Rhythm Pharmaceuticals Q3 Loss Narrows, Revenue Rises; Shares Down Pre-Bell

Rhythm Pharmaceuticals reported third-quarter 2026 net product revenue of $92.1 million, up 29% sequentially, and a net loss attributable to common stockholders of $42.4 million. The company said U.S. launch momentum for IMCIVREE in acquired hypothalamic obesity continued, with more than 700 patien…